IXICO plc (AIM:IXI)
London · Delayed Price · Currency is GBP · Price in GBX 7.85
+0.10 (1.29%)
At close: Mar 4, 2026
IXICO Revenue
In the fiscal year ending September 30, 2025, IXICO had annual revenue of 6.53M GBP with 13.32% growth. IXICO had revenue of 3.33M in the half year ending September 30, 2025, a decrease of -3.93%.
Revenue
6.53M
Revenue Growth
+13.32%
P/S Ratio
1.11
Revenue / Employee
82.71K
Employees
79
Market Cap
7.27M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 6.53M | 768.00K | 13.32% |
| Sep 30, 2024 | 5.77M | -899.00K | -13.49% |
| Sep 30, 2023 | 6.67M | -1.98M | -22.89% |
| Sep 30, 2022 | 8.64M | -547.00K | -5.95% |
| Sep 30, 2021 | 9.19M | -342.00K | -3.59% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Futura Medical | 7.93M |
| Fusion Antibodies | 1.60M |
| OptiBiotix Health | 1.15M |
| Oxford BioDynamics | 1.10M |
| ValiRx | 49.78K |
| CRISM Therapeutics | 25.00K |
IXICO News
- 3 months ago - IXICO plc (PHYOF) Q4 2025 Earnings Call Transcript - Seeking Alpha